Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines by unknown
PRECLINICAL STUDIES
Molecular mode of action of NKP-1339 – a clinically investigated
ruthenium-based drug – involves ER- and ROS-related effects
in colon carcinoma cell lines
Lea S. Flocke1 & Robert Trondl1,2 & Michael A. Jakupec1,2 & Bernhard K. Keppler1,2
Received: 15 February 2016 /Accepted: 1 March 2016 /Published online: 18 March 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Sodium trans-[tetrachloridobis(1H-indazole)
ruthenate(III)] (NKP-1339) is a clinically investigated
ruthenium-based metal complex, which shows promising
results in solid tumors, such as non-small cell lung can-
cer, colorectal carcinoma, and most distinctively in gas-
trointestinal neuroendocrine tumors. In previous studies,
fast binding to albumin as well as transferrin could be
shown. The enhanced permeability and retention (EPR)
effect, which is diversely being exploited for tumor
targeting, could therefore be applicable for NKP-1339.
Here we studied the serum dependence of its biological
activity in various methods, influencing its cellular ac-
cumulation, cytotoxicity as well as the generation of
reactive oxygen species (ROS). ROS lead to Nrf2 acti-
vation, which is known to activate antioxidant response
gene transcription. GRP78 down-regulation on the pro-
tein level suggests ER associated protein degradation
(ERAD) as a mode of action, as RNA levels are only
mildly affected. Another important part for the mode of
action is endoplasmic reticulum (ER) stress, as different
factors are highly upregulated on the protein level. For exam-
ple PERK, a transmembrane receptor which is released by
GRP78 when the ER is disturbed, is upregulated and phos-
phorylated. EIF2α is phosphorylated, which leads to an inhi-
bition of CAP-dependent translation and other stress re-
sponses. The transcription factor CHOP (DDIT3), which pro-
motes ER stress dependent apoptosis, is time and concentra-
tion dependently upregulated. Finally cytotoxicity tests could
prove that inhibition of ER stress and ER stress-mediated ap-
optosis leads to decreased cytotoxic effects of NKP-1339,
which highlights the involvement of this mechanism in the
mode of action.
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Introduction
The idea of ruthenium-based cancer chemotherapy is fueled by
the facts that some ruthenium compounds accumulate preferably
in tumor tissue, ruthenium has, compared to platinum(II), addi-
tional coordination sites, and a variety of ruthenium complexes
show redox behavior under physiological conditions. As
ruthenium-based complexes tend to show lower general toxic-
ities than platinum-based drugs, higher doses can be adminis-
tered [1, 2]. Three ruthenium-based compounds have been in-
vestigated in clinical studies recently, namely NAMI-A, KP1019
and NKP-1339. KP1019 and NKP-1339 bind to transferrin and
albumin very fast, whereby adduct formation with albumin is
preferred to transferrin [3, 4], and can thereby take advantage
of drug delivery by the enhanced permeability and retention
(EPR) effect. The EPR effect leads to enhanced accumulation
of macromolecules (> 40 kDa), such as albumin, in solid tumors,
where they are retained for many hours due to a lack of efficient
lymphatic drainage [5]. The serum concentration was shown to
have a significant impact on the P-glycoprotein-modulating
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activity of KP1019 in the leukemia cell line HL60 [6]. In cell
culture, binding of KP1019 or NKP-1339 to albumin leads to a
decrease in activity, as no EPR effect can be observed and con-
ditions in vitro are therefore probably less favorable for protein-
mediated uptake into cancer cells. Once NKP-1339 is delivered
to the cell, it can exhibit its cytotoxic activity.
Evidence for clinical anticancer effects of NKP-1339 was
already reported from a phase I dose-escalation study where
dose proportionality of Cmax and AUC0–192 of the first dosing
interval could be observed. Furthermore, patients with gastro-
intestinal neuroendocrine tumors have experienced partial re-
sponse or disease stabilization. Stable disease could be ob-
served for a wide variety of tumors, including non-small cell
lung cancer (NSCLC), sarcoma and colorectal cancer. The
adverse effects are manageable, most commonly mild to mod-
erate nausea, vomiting and fatigue [7].
As enhanced ER stress is a promising strategy against can-
cer [8], we investigated its role in the mode of action of NKP-
1339. The ER is the organelle which is in charge of correct
protein maturation, folding and secretion. If too many
misfolded proteins are accumulated, the ER starts the unfold-
ed protein response (UPR). If only mild disturbances occur, it
enables the organelle by stopping the cell cycle to repair dam-
ages, but if a certain threshold is exceeded it can induce apo-
ptosis. It is a mechanism executed via three branches. The
three transmembrane receptors PERK, ATF6 and IRE1α are
bound by GRP78, which senses and binds damaged proteins,
thereby releasing the receptors and starting UPR signaling.
The first transmembrane receptor which is released is
PERK. Thereupon eIF2α is phosphorylated, which inhibits
CAP-dependent translation. ATF4 is CAP-independent and
therefore upregulated following eIF2α phosphorylation. The
transcription factor ATF4 translocates to the nucleus and in-
duces stress response, expression of genes for amino acid
transport and synthesis, and finally CHOP [9]. CHOP is a
protein which is involved in the switch to apoptosis and in-
duces Bcl2 downregulation and DR5 (death receptor 5) acti-
vation. Activated PERK also leads to a translocation of Nrf2,
which is followed by upregulation of genes having an antiox-
idant response element (ARE) in their promotor, e.g., heme
oxygenase 1 (HO-1) and glutathione S-transferase (GST)
[10]. When ATF6 is released from GRP78, it is cleaved and
translocates to the nucleus. In the nucleus, different chaper-
ones as well as genes for protein degradation are upregulated.
In addition, XBP1 is spliced, which is also triggered by release
of the third transmembrane receptor IRE1α from GRP78.
Splicing of XBP1 mRNA leads to a frameshift and thereupon
translation into the functional protein, which, after transloca-
tion to the nucleus, activates gene expression of chaperones,
as well as genes for protein degradation and p58IPK. P58IPK
downregulates eIF2α phosphorylation, as well as ATF4 up-
regulation and CHOP activation via a negative feedback loop
[11].
In this study, we reveal the involvement of ER stress in the
mode of action of NKP-1339 via Western blotting analysis
showing upregulated PERK, p-eIF2α and CHOP. ROS are gen-
erated and Nrf2 translocates to the nucleus. Activity is enhanced
when serum concentration is reduced, reflecting reduced binding
of NKP-1339 to serum proteins, which is considered advanta-
geous only in vitro, though (for reasons explained above).
Materials and methods
Reagents and antibodies
NKP-1339 was synthesized as previously reported [12], dis-
solved in DMSO (40 or 80 mM stocks) and diluted to final
concentrations in cell culture medium.MEM, PBS and trypsin
were purchased from Sigma-Aldrich (Vienna, Austria). Nrf-2
and 2° FITC coupled antibodies were purchased from Santa
Cruz Biotechnology (Dallas, TX, USA). Cycloheximide
(CHX) and c-Jun N-terminal kinase (JNK) inhibitor
SP600125 were purchased from Abcam (Cambridge, UK).
The antibodies against GRP78, p-eIF2α, PERK and β-actin,
as well as horseradish peroxidase-labeled anti-mouse igG and
anti-rabbit igG were purchased from Cell Signaling
Technology (Danvers, MA, USA).
Cell culture
HCT116 and SW480 (both human colorectal carcinoma) cells
were provided by Brigitte Marian (Institute of Cancer
Research, Department of Medicine I, Medical University of
Vienna, Austria). Cells were grown in Eagle’s minimal essen-
tial medium containing 10 % FCS, 1 mM sodium pyruvate,
4 mM L-glutamine and 1% non-essential amino acids at 37 °C
under 5 % CO2 and humidified conditions. Cells were pas-
saged twice a week and seeded for experiments in exponential
growth phase 24 h before treatment. Cell lines where authen-
ticated and proven to be free of any contamination with my-
coplasma by Multiplexion (Heidelberg, Germany).
Cellular accumulation
120 000 cells/ml were seeded in 2.5 ml complete MEM per
well into 6-well plates (CytoOne, Starlab, UK), allowed to
settle and recover for 24 h, washed 3 times with 3 ml PBS
each and then treated with 100 μM NKP-1339 or medium
alone, each containing 2 %, 5 % or 10 % FCS for 2 h. The
cells were washed again 3 times with 3 ml PBS. The same
treatment was performed to a parallel plate, three replicates for
each treatment, from which cells (instead of being lysed by
acid treatment) were detached by trypsinization for counting
of cell numbers. The samples were treated by addition of
500 μl subboiled HNO3. Cell lysis was left for 1 h and then
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400 μl of the sample were added to 7.6 ml ddH2O and ana-
lyzed by ICP-MS as described previously [13]. Three inde-
pendent biological replicates were performed, each with three
technical replicates.
MTTassay
Cytotoxicity was assessed by the MTT assay. 2000 cells were
seeded per well in 100 μl complete MEM into 96-well plates
(CytoOne, Starlab, UK), allowed to settle and recover for
24 h, washed twice with PBS, and then 100 μl MEM contain-
ing 2 % or 10 % FCS were added either alone or containing
CHX or JNK inhibitor. The test compound was dissolved in
DMSO, appropriately diluted in MEM and added to the cells
in 100 μl per well in triplicates. Incubation with the test com-
pound alone or in combination with the inhibitors took place
in the incubator at 37 °C, 5 % CO2 under humidified condi-
tions for 96 h. CHX was used in a concentration of 1.25 μM
and JNK in 10 μM (those concentrations were found to be the
highest not inhibiting cell proliferation alone). Then MEM
was replaced with 6× RPMI1640 medium: 1× MTT (3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide)
solution in phosphate-buffered saline (5 mg/ml). After 4 h,
the RPMI1640/MTT solution was removed and the formed
formazan dissolved in 150 µl DMSO per well. Absorption
was measured at 550 nm (and 690 nm as a reference wave-
length) with a microplate reader (Biotek ELx808).
Concentration–effect curves were calculated relative to un-
treated controls, and IC50 (50 % inhibitory concentration)
values were interpolated. Results are means ± standard devi-
ations from at least three independent experiments.
2′,7′-Dichlorofluorescin diacetate (DCFH-DA) assay
Twenty-five thousand cells were seeded in 100 μl complete
MEM per well in a 96-well plate (CytoOne, Starlab, UK).
Cells were allowed to settle and recover for 24 h and washed
once with Hanks Balanced Salt Solution (HBSS) supplement-
ed with 1 % FCS. The cells were then incubated for 45 min at
37 °C with 25 μM DCFH-DA stock (1 % DMSO in HBSS
containing 1% FCS) and then treated inMEMwithout phenol
red containing 2 %, 5 % or 10 % FCS. 200 μM H2O2 were
used as positive control and pure MEM without phenol red
containing 2 %, 5 % or 10 % FCS as negative control. NKP-
1339 was dissolved in DMSO to 40 mM, diluted inMEM and
added to the cells at final concentrations of 50 μM, 100 μM
and 200 μM. Fluorescence was measured over 14 h every
10 min with the multi-mode microplate reader Synergy HT
(Biotek) (excitation: 480 nm/emission: 516 nm). Results are
presented as treated over control. Two independent biological
replicates were performed, each with three technical
replicates.
Immunofluorescence microscopy
Two-hundred thousand cells were seeded on cover slips in a 6-
well plate (CytoOne, Starlab, UK) to achieve a 40–70 % con-
fluence 24 h later (on the day of fixation). Liquid was aspired
and cells covered for 15 min in 2.5 ml 4 % formaldehyde
diluted in 37 °Cwarm PBS. Cells were washed three times with
PBS and 60 min blocked in 1 ml blocking buffer (1× PBS, 5 %
BSA, 0.3 % Triton-X™ 100). Then 1° antibody anti-Nrf-2 was
added 1:100 in antibody dilution buffer (1× PBS, 1 % BSA,
0.3 % Triton-X™ 100) and incubated over night at 4 °C. The
cells were then washed three times, each for 5 min with 2 ml
PBS, and then incubated with FITC labeled 2° anti rabbit AB
for 2 h at room temperature in the dark. The cells were washed
three times, each 5 min with 2 ml PBS, again and 300 nM
DAPI in PBS added to the cells for 5 min. Then cells were
rinsed several times with PBS and finally mounted in PBS, to
be viewed under the fluorescence microscope using the appro-
priate filters. FITC is excited at 485 nm giving an emission of
514 nm. A BX40 fluorescence microscope with an F-View
CCD Camera, Cell^F fluorescence imaging software, and oil
immersion objective lens (60× magnification) (all from
Olympus, Vienna, Austria) were used. DAPI is excited at
358 nm giving an emission of 561 nm. At least three indepen-
dent biological replicates were performed, each with about 100
cells analyzed.
Western blotting
Two-hundred thousand cells were seeded into 6-well plates
(CytoOne, Starlab, UK), allowed to settle and recover for
24 h, washed twice with PBS, and then 2 ml MEM containing
2 % or 10 % FCS were added. Then 50 μM, 100 μM or
200 μMNKP-1339 were added for the indicated time periods.
0.5 mM thapsigargin (TG) were used as positive control.
Proteins were extracted by lysis with radioimmunoprecipitation
assay (RIPA) buffer including 1× protease and 1× phosphatase
inhibitor cocktails (Sigma-Aldrich). Per blot, the same amount
of protein per lane was electrophoretically separated by size
and blotted onto a polyvinylidene fluoride (PVDF) membrane
by using a semi-dry blotter (Peqlab, Erlangen, Germany). Then
the membrane was blocked for 1 h at room temperature with
5 % BSA in Tris-buffered saline/Tween 20 buffer. The 1° anti-
body was diluted in 5 % BSA in Tris-buffered saline/Tween 20
buffer according to manufacturer guidelines and incubated at
4 °C over night. Anti-β-actin was used as loading control. The
membrane was washed three times with 5 ml PBS and the 2°
antibody coupled to horseradish peroxidase was diluted 1:
2000 in 5 % BSA in Tris-buffered saline/Tween 20 buffer
and incubated for 1 h at room temperature. Pierce
SuperSignal Enhanced chemoluminescent (ECL) substrate
(Thermo Fisher Scientific, Inc., Rockford, IL) was incubated
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for 5 min and detected by a Fusion FX7 chemiluminescence
detection system (Vilber Lourmat, Eberhardzell, Germany).
Reverse transcriptase quantitative PCR (rt qPCR)
High purity RNA was extracted from monolayer cells by
using RNeasy Mini Kit (Qiagen, Vienna, Austria) follow-
ing manufacturer guidelines. cDNA was reversely tran-
scribed by using High-Capacity Reverse Transcription Kit
(Applied Biosystems, Bleiswijk, Netherlands) following
manufacturer guidelines. Rt qPCR was performed by using
a Rotor Gene Q instrument (Qiagen, Vienna, Austria). For
Eva Green-based amplification assessment 10 ng template/
rxn were amplified with 10 μM forward and reverse primer
and 1× HOT FIRE Pol® EvaGreen® qPCR Mix Plus
(Medibena, Vienna, Austria). For probe-based amplifica-
tion assessment (for XBP1 spliced) 10 ng template/rxn
were amplified with 10 μM forward and reverse primer,
10 μM spliced and unspliced probe and 1× HOT FIRE
Pol® Probe qPCRMix Plus (ROX). All genes were normal-
ized to the reference gene Oaz. The temperature protocol
initiated a hot start: 15 min, 95 °C. Then 40 cycles of 60 s
60 °C, 30 s 95 °C. The high-resolution melting curve was
analyzed to ensure that the amplified region was the one of
interest. The primer sequences as well as the hydrolysis
probes were designed by using Primer Express software
(version 2.0; Applied Biosystems, Vienna, Austria).
Specificity was investigated by Primer-BLAST (NCBI,
NIH). A series of 10-fold dilutions of a control cDNA from
SW480 or HCT116 cells amplified in duplicates was used
to generate a standard curve. The amplification efficiencies
were calculated from the slope of the dilution row and were
at least 88 %. The n-fold relative amplification from treated
to untreated was calculated. At least three independent biological
replicates were performed, each with two technical replicates.
Statistical analysis
Results were analyzed by one-way ANOVA by using
GraphPad Prism (version 5.0; GraphPad Software, Inc., La
Jolla, CA). The significance level for the test is 5 %.
Results
In this study, we could show by ICP-MS measurements that
the extent to which NKP-1339 is taken up into the cell within
2 h strongly depends on the serum content (2 %, 5 % or 10 %)
of the medium. In both colon carcinoma cell lines, ruthenium
accumulation is negatively correlated to the serum concentra-
tion (Fig. 1). One-way ANOVAproves a significant difference
between 2 % FCS and 10 % FCS in HCT116 cells. Overall,
SW480 cells show a higher cellular accumulation and slightly
lower serum dependency (with a discernible trend, but not
reaching the significance level) than HCT116 cells.
SW480 and HCT116 are both epithelial, adherent cell lines
from the same histological background (colon carcinoma) but
are known to show different chemoresistance profiles. To study
the influence of serum concentration on the cytotoxic properties
of the ruthenium complex, MTT assays were performed, and
pronounced differences in IC50 values could be observed. In
good accordance with the cellular accumulation experiments,
NKP-1339 exerts higher cytotoxicity if less of serum is present
(Fig. 2). The IC50 value is four times increased in HCT116 cells
if the serum concentration is raised from 2% to 10%. Compared
to this cell line, the cytotoxicity in SW480 cells is only mildly
reduced by increased serum content. Remarkably, the sensitivity
to NKP-1339 at low serum concentration is lower in the P-
glycoprotein (P-gp) overexpressing cell line SW480 despite a
tendency for slightly higher cellular ruthenium accumulation.
This might indicate the presence of some kind of intrinsic resis-
tance independently of P-gp.
The DCFH-DH stained cells showed that NKP-1339 induces
elevated levels of ROS. The level of induced ROS is inversely
correlated to the serum concentration. This correlation again
stresses the importance of serum content for the effectivity of
the ruthenium compound. We quantified the levels of ROS over
14 h and chose 1 h as themost distinctive time point to show that
ROS levels in both cell lines are comparable, and both consis-
tently show an inverse relationship between ROS formation and
serum concentration (Fig. 3). Results for a 2 h time course are
shown in Fig. S1 (supplementary data).
The well-known transcription factor Nrf2 was found to be
translocating to the nucleus upon treatment with NKP-1339.
In Fig. 4 translocation is shown after 6 h hours with 2% serum
concentration in the medium. Overall, translocation seems to
be more pronounced in SW480 than in HCT116 cells. In the
nucleus, Nrf2 is known to activate genes that contain antiox-
idant response elements (ARE) in their promoter region.



















Fig. 1 Influence of serum content on cellular accumulation of Ru (from
NKP-1339) in the two colon carcinoma cell lines HCT116 and SW480
(n = 3). Cells were treated for 2 h with 100 μM NKP-1339 in media
containing different serum concentrations (2 %, 5 % or 10 % as
indicated). An inverse correlation between cellular accumulation and
serum content could be observed
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In this study, we could show that three important key fac-
tors of ER stress are highly upregulated on the protein level
upon 24 h exposure to NKP-1339. The transmembrane recep-
tor protein kinase R (PKR)-like endoplasmic reticulum kinase
(PERK), which is encoded by the gene EIF2AK3, is phos-
phorylated as the band is shifted and vanishes at very high
concentrations of NKP-1339. This effect is less pronounced in
SW480 cells, where the phosphorylation is only visible in
cells treated in medium containing 10 % serum. The phos-
phorylation upon NKP-1339 treatment at up to 100 μM leads
to an activation of the kinase. The degradation at higher con-
centrations of NKP-1339might be caused by ERAD aswill be
discussed below. The 78 kDa glucose-regulated protein
(GRP78, also BiP or HSPA4) – a chaperone which senses
damaged proteins by binding hydrophobic patches [14] – is
upregulated when cells are treated with low concentrations of
NKP-1339, but when 100 μMare applied in media containing
10 % FCS or when 200 μM are applied in cells treated in
media containing 2 % FSC the protein approaches the basal
level again. In SW480 cells degradation of GRP78 after
treatment with 200 μM NKP-1339 is observed. PeIF2α is
upregulated, but this effect becomes less distinct at high con-
centrations of NKP-1339. CHOP, which is responsible for the
switch from the pro-survival mode of UPR to proapoptotic
signaling, is overexpressed in both cell lines, HCT116 and
SW480. In HCT116 cells, this transcription factor shows a
pronounced activation when cells were treated in medium
containing 2 % FCS but not when in medium containing
10 % FCS.
To further investigate the role of ER stress in the cellular
effects of NKP-1339, different key factors were analyzed on
the mRNA level at various time points from 1 h to 48 h. To
illustrate effects on the mRNA level in Fig. 6, data from 4 h
exposure experiments are displayed, which is shorter than that
used in Western blotting experiments (24 h) which showed
pronounced changes in expression of certain factors. CHOP
mRNA expression is upregulated in both cell lines when cells
were grown in media containing 2 % or 10 % FCS.
Interestingly, the effects in HCT116 cells are more pro-
nounced when the serum concentration is 10 %. Similar re-
sults were obtained for spliced XBP1 which via a frameshift
during splicing leads to expression of the functional protein. In
HCT116 cells, the XBP1 splicing effect is more pronounced
in cells treated in medium containing 2 % FCS, whereas in
SW480 cells again the more pronounced effect is observed in
medium containing 10 % FCS. The other factors: ATF4,
IRE1α as well as GRP78 show no pronounced alterations
on the mRNA level at any incubation time.
GRP78 was found to be downregulated on the protein level
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Fig. 2 Cytotoxicity of NKP-1339 in the two colon carcinoma cell lines
HCT116 and SW480 treated in medium containing 2 % or 10% FCS and
co-treatment with inhibitors of ER stress or responses thereto (n = 3).
Cytotoxicity is illustrated by the half maximal inhibitory concentration
(IC50). Cytotoxicity is increased when serum concentration is reduced in
both cell lines. Inhibiting protein translation by CHX as well as inhibiting
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Fig. 3 Generation of reactive oxygen species (ROS) in HCT116 and
SW480 cells after 1 h treatment with 200 μM NKP-1339 (n = 2) in the
presence of different serum concentrations. The relative fluorescence
units plotted on the y-axis indicate ROS levels, which are inversely
dependent on serum content of the medium
Fig. 4 Nrf2 translocation. Cells treated for 6 h in medium containing 2%
FCS. Upon treatment with NKP-1339, Nrf2 is translocating to the
nucleus. Pictures depict typical results. Scale bar applies to all images
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containing 10 % FCS (Fig. 5), whereas for GRP78 no effect
on mRNA expression was found, which suggests that
ER-associated protein degradation (ERAD) is involved.
ERAD is known to be induced by ER stress [15] to reduce
the protein burden for the organelle, and as NKP-1339 induces
ER stress ERAD seems plausible (Fig. 6).
Finally, the relevance of ER stress for the mode of action of
NKP-1339 was investigated by combined application of
NKP-1339 with specific inhibitors of ER stress or cellular
responses thereto. CHX is produced by the bacterium
Streptomyces griseus and an inhibitor of eukaryotic protein
synthesis by preventing translational elongation. This leads
to a reduced protein load for the ER, which can relieve ER
stress. The c-Jun N-terminal kinase (JNK) inhibitor SP600125
inhibits c-Jun N-terminal kinase ATP-competitively, which
prevents ER stress-induced apoptosis. Both inhibitors are able
to slightly decrease the cytotoxic properties of NKP-1339 in
both colon carcinoma cell lines, with IC50 values increasing
by 21 % for CHX in HCT116 cells and by 70 % for CHX in
SW480 cells. The JNK inhibitor SP600125 leads to increases
of IC50 values by 33 % in HCT116 cells and 58 % in SW480
cells (Fig. 2).
Discussion
This study gives valuable insights into the mode of action of the
clinically investigated ruthenium complex NKP-1339 in the two
colon carcinoma cell lines HCT116 and SW480. Colon carcino-
mas are highly mutated tissues and can be characterized by mu-
tations causing resistance, such as in p53, and phenotypic chang-
es such as upregulation of Bcl2 and multidrug resistance (MDR)
genes. It was shown previously that NKP-1339 reacts fast with
the protein albumin [16], which is the most abundant protein in
human serum with a concentration of about 600 μM [17] and
contained in FCS used for cell culture as well. Albumin is accu-
mulated in tumor tissue based on the EPR effect, which, howev-
er, is not reflected in cell culture settings. As a result, binding to
albumin, though desirable for the tumor selectivity it may medi-
ate in vivo, seems disadvantageous in vitro as it leads to de-
creased activity of the compound. The EPR effect is, however,
only one of the components contributing to enhanced albumin
uptake into tumor tissue. The second major albumin uptake
mechanism is the gp60/SPARC-activated pathway (gp60 is a
60-kDa endothelial cell membrane albumin-binding protein lo-
calized in caveolae; SPARC stands for secreted protein, acidic
and rich in cysteine) as well as hyperactive caveolae transport. In
patients with advanced solid tumors, a third pathway can be
activated in association with hypoalbuminemia (decreased se-
rum albumin level) [18]. Cellular accumulation studies revealed
an inverse correlation between serum content and cellular accu-
mulation, which explains why the compound shows a lower
cytotoxic potency when serum content is increased to the usual
value. Altogether this clarifies whyNKP-1339 is poorly active in
the cell culture setting in contrast to its therapeutic efficacy (with
mild side effects) in patients with solid tumors in clinical studies
[7]. Accumulation and long retention in tumor tissue may com-
pensate for the drop in activity initially elicited by serum protein
binding. In vitro, however, high drug concentrations are required
to be able to detect appreciable activity, since serum proteins tend
to obscure its cellular effects.
Effects of serum proteins on the biological activity have
occasionally been reported in the literature also for other an-
ticancer ruthenium complexes. The consequences of albumin














































































































SW480 2%FCS SW480 10%FCS
P-eIF2α [38 kDa]
Fig. 5 Western blot analysis showing p-eIF2y α and CHOP
upregulation, PERK phosphorylation as well as Grp78 regulation
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Fig. 6 Rt qPCR ofUPR key factors in two cell lines upon 4 h exposure to
NKP-1339 in media containing 2 % or 10 % FCS (n = 3). GRP78, ATF4
and IRE1α show no major upregulation on the mRNA level (a). CHOP
and XBP1 are slightly or even distinctly upregulated. CHOP shows the
highest upregulation in HCT116 cells treated in medium containing 10 %
FCS, and XBP1 in SW480 cells treated in medium containing 10 % FCS
(b). Note the differently scaled x-axes
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ligands were shown to be divergent, depending on their ten-
dency for hydrophobic versus coordinate protein interactions
[19]. In the cell culture setting, the more easily reversible non-
coordinate interactions are favorable for cytotoxicity, whereas
coordinate binding tends to decrease it, in line with our results.
For the clinically developed anticancer Ru(III) compound
NAMI-A, decreased effects on cell cycle progression as well
as cell viability upon adduct formation with albumin or trans-
ferrin were shown as well [20]. The re-adhesion rate (as an
aspect of the metastatic process inhibited by NAMI-A) of
cancer cells was reported to be only slightly (though signifi-
cantly) less reduced when NAMI-A is applied in albumin-
bound form in vitro, suggesting that biological activity is ba-
sically maintained [21].
NKP-1339 was also shown to induce elevated levels of
reactive oxygen species in an inversely serum-dependent
manner, which further stresses the influence of serum proteins.
Both cell lines show similar ROS levels, but IC50 levels in
SW480 cells are higher (at least for 2 % FCS); this implies
that the cell line HCT116 is more sensitive towards ROS than
SW480. For KP1019 (the indazolium salt analog of NKP-
1339), it was shown in previous studies that cytotoxicity is
reduced by N-acetylcysteine (NAC) addition, suggesting an
important role for ROS in the mode of action [22]. ROS are
known to induce Nrf2 translocation from the cytoplasm into
the nucleus. In the nucleus, this transcription factor induces
different genes containing an ARE in their promotor site. We
could show that translocation of Nrf2 upon NKP-1339 expo-
sure indeed occurs in colon cancer cell lines. Further ROS lead
to protein damage, which leads to an accumulation of
misfolded proteins in the ER. Because of enhanced and fast
metabolism, cancer cells show an increased level of oxidative
stress and ER stress [8]. After exceeding a certain threshold,
UPR signaling indicates ER stress, which we could confirm
on the protein level. GRP78 as a major ER resident chaperone
is one of the key sensors of protein damage, a key regulator of
ER stress and responsible for processing of misfolded pro-
teins. It has been proposed as a major target for NKP-1339
(Dickson et al., 2011). Furthermore, GRP78 is correlated with
poor patient survival, high pathological grade and relapse in
breast, liver, prostate and gastric cancer, as well as colon car-
cinoma; therefore, it could be applied as a biomarker. The
chaperone inhibits activation of caspase 7, cytochrome C
release as well as of the BH3-only proapoptotic proteins
Bik and Bax [23]. We could find that the chaperone is reg-
ulated on the protein level but only mildly influenced on the
mRNA level, which suggests a certain involvement of
ERAD in the mode of action of NKP-1339. The relevance
of ER stress for the cytotoxic properties of the ruthenium
compound was confirmed by showing that IC50 values are
significantly increased when ER stress is inhibited by CHX
as well as when ER stress-induced apoptosis is inhibited by
a JNK inhibitor.
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